https://www.phronesisai.com/blog daily 0.75 2025-06-23 https://images.squarespace-cdn.com/content/v1/6859db72168baf4d2384e4e3/1750719364456-5NIOF8QADB1LE9JDSUJM/Childers+headshot.jpg https://images.squarespace-cdn.com/content/v1/6859db72168baf4d2384e4e3/1750719364461-KVJHHM4QQXBR8LI4ZZL8/AI+Risk+Reward+Logo.png https://images.squarespace-cdn.com/content/v1/6859db72168baf4d2384e4e3/1750719364466-XUBFPFEX436WFWHOXT7L/Childers+headshot.jpg https://images.squarespace-cdn.com/content/v1/6859db72168baf4d2384e4e3/1750719364473-14LDXHJC71MIUCYFJBIR/BIoRXiv.png https://images.squarespace-cdn.com/content/v1/6859db72168baf4d2384e4e3/1750719364480-8DTX2LCTMNFWTAV2EIHI/Lime+Drug+Design.png https://images.squarespace-cdn.com/content/v1/6859db72168baf4d2384e4e3/1750719364488-MJGC97JV7OF5CSLLNYES/UCI_primarylogo_webblue.png https://images.squarespace-cdn.com/content/v1/6859db72168baf4d2384e4e3/1750719364491-9ZKQV520CZ3WYFVSGKD4/download.jfif https://images.squarespace-cdn.com/content/v1/6859db72168baf4d2384e4e3/1750719364498-HNS9KKJ75RD6993JCW7W/image_50375937.JPG https://images.squarespace-cdn.com/content/v1/6859db72168baf4d2384e4e3/1750719364506-4ZF3Y3F9BHV23WY8A3QI/LSX.png https://images.squarespace-cdn.com/content/v1/6859db72168baf4d2384e4e3/1750719364514-H0RCIY0493OYC3YTT14R/Lime+pic+blog+1.png https://www.phronesisai.com/blog/a-drug-design-company-cebz4 monthly 0.5 2026-02-27 https://www.phronesisai.com/blog/tag/Phronesis+AI monthly 0.5 https://www.phronesisai.com/blog/tag/Our+Story monthly 0.5 https://www.phronesisai.com/blog/tag/LIME monthly 0.5 https://www.phronesisai.com/blog/tag/Artificial+Intelligence monthly 0.5 https://www.phronesisai.com/blog/tag/Drug+Design monthly 0.5 https://www.phronesisai.com/about daily 0.75 2025-07-10 https://images.squarespace-cdn.com/content/v1/6859db72168baf4d2384e4e3/1750719346691-ICZQO97X4OHFCOKNPDK1/logo-no-background.png https://www.phronesisai.com/wayne-childers daily 0.75 2025-06-23 https://images.squarespace-cdn.com/content/v1/6859db72168baf4d2384e4e3/1750719348874-ZF23YQZFZORQLAM5HCRX/Childers+headshot.jpg Dr. Wayne Childers - Wayne Childers, Ph.D. Dr. Wayne Childers is a medicinal chemist whose experience encompasses small molecules, peptides, molecular glues and protein degraders. He is currently a Professor of Medicinal Chemistry at Temple University School of Pharmacy and Associate Director of the Moulder Center for Drug Discovery Research, an academic drug discovery center founded in 2010. Wayne’s research interests include structure- and ligand-based drug design in a variety of therapeutic areas, including cancer, diseases of the CNS, metabolic disorders and microbial infection. Wayne received his b achelor’s degree in chemistry from Vanderbilt University in 1979 and his Ph.D. in organic chemistry from University of Georgia in 1984. He trained as a postdoctoral fellow at The Johns Hopkins University School of Medicine before accepting a position with Wyeth Research in 1987. While at Wyeth, teams under Wayne’s leadership advanced five compounds to development . In 2010 Wayne joined Temple University and was promoted to Full Professor in 2023. Intellectual property generated in his labs has been licensed to three companies for development, and Wayne is a co-founder of one of those companies. Wayne is an author on over 50 peer-reviewed research publications as well as a number of reviews, perspectives, book chapters. He is an inventor on over 60 patents and patent applications. Wayne is co-editor of the Wiley book series Successful Drug Discovery as well as the upcoming Wiley book series Trends in Drug Discovery. He serves as a scientific advisor for a number of companies, including Rapafusyn Pharmaceuticals, NatPro Pharmaceuticals and Recombination Therapeutics. https://www.phronesisai.com/michael-leventhal daily 0.75 2025-06-23 https://images.squarespace-cdn.com/content/v1/6859db72168baf4d2384e4e3/1750719350558-U1OBRZMHX93DWVIDA6SU/Michael-Bio-Pic.jpg Michael Leventhal - Michael Leventhal Michael Leventhal specializes in providing corporate, intellectual property, and business transactional services for media/entertainment and technology companies, as well as strategic guidance for clients navigating the tech and finance worlds. Working with entrepreneurs and visionaries at all stages of development has long been one of Michael’s passions. Recently, Michael served as chief legal officer and vice president at Magic Leap, Inc., the well-known augmented/mixed reality venture, and served an instrumental role in the facilitation of their $3.65 Billion cap raise. https://www.phronesisai.com/robert-derham daily 0.75 2025-06-23 https://images.squarespace-cdn.com/content/v1/6859db72168baf4d2384e4e3/1750719351456-W618DMDFHOOTPF0L1EI8/robert+Image.jpg Robert Derham - Dr. Robert Derham, Ph.D Immunology With extensive experience with rare diseases and orphan products, I provide value in: --Partnering and business development for orphan product / rare diseases / precision medicine --Strategic corporate planning with rare diseases and orphan products --Development change for rare diseases and orphan products --Orphan drug product road map planning (preferably preclinical period, but also later stages) --Cultural change to an orphan drug company --Commercialization strategies for orphan drugs / orphan products --Product launch planning for orphan drugs / orphan products GOALS: -Ensure the best products for patients are partnered between the right companies for rare diseases / orphan products -Architect, plan and implement something that has never been done before -Continue developing creative solutions to ensure success -Maximize sales, product branding and company recognition through strategic marketing / communication strategies -Always work with passionate people https://www.phronesisai.com/kirk-hasserjian daily 0.75 2025-06-23 https://images.squarespace-cdn.com/content/v1/6859db72168baf4d2384e4e3/1750719353029-TWEIJ3QZVJ8KCVI2J6VQ/KirkBioPic.jpg Kirk Hasserjian - Kirk Hasserjian Kirk Hasserjian has been in the high technology arena for over 38 years. He was the corporate vice president in Applied Global Services and lead the Service Product Development organization. His group was responsible for creating comprehensive service products utilizing artificial intelligence and machine learning techniques to improve all aspects of tool performance for Applied’s customers. Mr. Hasserjian served in a variety of technical and management roles at Intel and FormFactor. He spent 25 years at Intel Corporation, where his responsibilities included leading Intel’s Flash memory technology development activities in NOR, NAND and future non-volatile memory technologies as Vice President and General Manager of California Technology and Manufacturing. Mr. Hasserjian received his bachelor of science degree in chemistry from the University of San Francisco and a master of science degree in chemical engineering from Stanford University. https://www.phronesisai.com/wayne-danter daily 0.75 2025-06-23 https://images.squarespace-cdn.com/content/v1/6859db72168baf4d2384e4e3/1750719353865-91RWFF4ZBD3D6CD8VGTV/Wayne_Headshot.png Wayne Danter, Ph.D. - Dr. Wayne R. Danter, MD, FRCPC Dr. Wayne Danter is the founder of 123Genetix Inc. and he is a pioneer at the evolving interface between artificial intelligence (“AI”) and pharmacogenomics (i.e., the study of how genetics affect a person's response to drugs). Dr. Danter is first person in the world to have drug go to clinical trials 100% evolved from AI. Dr. Danter has conducted extensive research on the medical application of AI technologies to disease diagnosis, outcome prediction, precision oncology, artificial stem cells and artificial organoids. His research has been published in many peer-reviewed journals and he has been an invited presenter and panelist at numerous international meetings. Prior to founding 123Genetix, Dr. Danter was the President, CEO, CSO and Director of Critical Outcome Technologies Inc., which he also founded. While at Critical Outcome Technologies, he invented a proprietary, AI-based technology platform that utilizes a series of predictive computer models to identify compounds with a high probability of successful development from disease specific drug discovery and chemical optimization through preclinical and early clinical testing. Dr Danter is also the inventor of the ROSALIND A.I. platform for Precision Oncology. Dr. Danter is a board certified in Internal Medicine with additional training in Clinical Pharmacology and Critical Care. Dr Danter was also a member of the Royal College of Physicians of Canada examination board for specialist licensure in Internal Medicine. Web: www.123Genetix.com https://www.phronesisai.com/neil-sahota daily 0.75 2025-06-23 https://images.squarespace-cdn.com/content/v1/6859db72168baf4d2384e4e3/1750719354728-1BOVE75WKX7AXXKRYOSF/NeilBioPic.jpg Neil Sahota - Neil Sahota Neil Sahota (萨冠军) is an IBM Master Inventor, United Nations (UN) Artificial Intelligence (AI) Advisor, Chief Innovation Officer at UC Irvine, and author of award-winning best business book of 2019, Own the A.I. Revolution. With 20+ years of business experience, he works with organizations to create their core business strategy, enter new markets, and develop next generation products/solutions powered by emerging technology. His work experience spans multiple industries including legal services, healthcare, life sciences, retail, travel and transportation, energy and utilities, automotive, telecommunications, media/communication, and government. Moreover, Neil is one of the few people selected for IBM's Corporate Service Corps leadership program that pairs leaders with NGOs to perform community-driven economic development projects. He is a member of several investor groups like the Tech Coast Angels, advises venture capital funds like Miramar and CerraCap, and helped create the UN’s Innovation Factory, a global program for social impact entrepreneurs. Neil also serves as a judge in various startup competitions and mentor in several incubator/accelerator programs. Neil cofounded the UN's AI for Good Initiative and is actively helping them building out their ecosystem of strategic partnerships. He is currently helping the Zero Abuse Project prevent child sexual abuse as well as Planet Home to engage youth culture in sustainability initiatives. Over the last twelve years, he has served as a Board Director to several non-profit organizations such as the OC Marathon and Cancer Computer as well as corporate boards from around the world like Legalmation, Lingmo, and Shineville. https://www.phronesisai.com/publications daily 0.75 2025-06-27 https://www.phronesisai.com/herman daily 0.75 2025-06-23 https://images.squarespace-cdn.com/content/v1/6859db72168baf4d2384e4e3/1750719357984-UT2DCMKLE6F7VVFKJ4NE/Herman+Sintim+Photo1.png Herman - Herman O. Sintim , Ph.D. Herman O. Sintim is a renowned figure in the field of chemistry and drug discovery, currently serving as a Distinguished Professor at Purdue University. With a BSc in Medicinal Chemistry from University College London and a Ph.D. in Organic Chemistry from the University of Oxford, Sintim has developed an impressive academic and professional trajectory. His postdoctoral tenures at both Oxford and Stanford Universities laid the foundation for his illustrious career in the field of chemistry and drug discovery. His move to Purdue University in 2015 as a professor in drug discovery marked a significant milestone, and he has since been awarded a Richard B. Wetherill Professorship. In addition to his academic roles, Sintim co-founded KinaRx LLC in 2017 and has contributed extensively to the scientific community, serving as Program Director at the NSF and participating in various editorial and advisory boards. His research interests span medicinal chemistry, chemical biology, and cyclic dinucleotide signaling, underscoring his commitment to advancing science in these critical areas. His work has garnered substantial external funding, and he has published extensively, with numerous journal articles and patents to his credit. https://www.phronesisai.com/will-spagnoli daily 0.75 2025-06-23 https://images.squarespace-cdn.com/content/v1/6859db72168baf4d2384e4e3/1750719358807-9PC2513TKHEKJ7XDMVKI/Will-Bio-Pic.jpeg Will Spagnoli - Will Spagnoli Will Spagnoli began his career as a serial entrepreneur and technology professional at the early age of 16. Leveraging technology to dominate the more experienced competition, he established multiple companies spanning a variety of industries, acquiring large-scale contracts across both private and government sectors. By his early 20s, Will discovered his passion for Machine Learning and set out with the goal of sharing the tremendous powers of Artificial Intelligence with the rest of the world ever since. Will Spagnoli is an expert in Deep Learning, Neural Network Architecture, Business Technology, and Machine Learning Solutions. Will is the original inventor for many of Phronesis AI's State-of-the-Art technologies. https://www.phronesisai.com/white-paper daily 0.75 2025-06-23 https://www.phronesisai.com/about123 daily 0.75 2025-07-10 https://www.phronesisai.com/projects daily 0.75 2025-06-23 https://images.squarespace-cdn.com/content/v1/6859db72168baf4d2384e4e3/1750719360609-HM9VVP3PVZNBLC90GRNI/23311.jpg Projects - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/6859db72168baf4d2384e4e3/1750719360612-W95Q6B7YKZCTY36SD8DA/Thomas+Lectka+picture.jpg https://images.squarespace-cdn.com/content/v1/6859db72168baf4d2384e4e3/1750719360615-ODEL2EKBCHFV59WJSRDU/Childers+headshot.jpg https://www.phronesisai.com/rick-fine daily 0.75 2025-06-23 https://images.squarespace-cdn.com/content/v1/6859db72168baf4d2384e4e3/1750719363628-AKJAT84L490CDBXFHU3O/IMG_4010.jpg Rick Fine - Rick Fine Richard J Fine is first and foremost an entrepreneur, the companies he has owned and operated revolved around his passion for making deals, and forming mutually beneficial partnerships. One of his companies, Resource Recycling, Int., built and operated four facilities in Ca, UT, and Washington, in the latter site the company reclaimed all of the Aluminum, Copper, and Steel for Kaiser Aluminum USA. Resource Recycling International, EROS Division signed the largest recycling contract with the Department of Defense in history, for all of the aircraft, parts, and engines of the US retired arsenal, valued at $5 billion. Further as a follow-on to this project provided the White Paper, with Rear Admiral Harry Fiske, for the decommissioning of the US Navy Fleet. His company Alabama Cathodic Metals focused on the chemical molecular processing for magnesium and its alloys. Through Turquesa Holdings, he horizontally developed a $300M, 265 unit project in Orange Beach Alabama, and $165 million hotel property in Fort Morgan Alabama. His company Fine Resources Inc consulted for some of the largest IT Asset Disposition companies in the world over a ten-year period. https://www.phronesisai.com/gary-bradski daily 0.75 2025-06-23 https://images.squarespace-cdn.com/content/v1/6859db72168baf4d2384e4e3/1750719366292-VD0JCUU7QLXLTWXCSW0X/Bradski+Headshot.png Gary Bradski - Gary Bradski Gary Bradski is a highly accomplished researcher and entrepreneur in the fields of computer vision and machine learning. He founded and is the CEO of OpenCV, the world's most popular computer vision library. He has also co-founded several startups, including Industrial Perception, which was acquired by Google in 2013, and he created the Silicon Valley office of Magic Leap. Bradski has a long list of patents and publications, and sits on the boards and advisory boards of several Silicon Valley companies. He has 20 years of industrial experience applying machine learning and computer vision, and has organized the computer vision team for Stanley, the autonomous car that kicked off the autonomous driving industry. Bradski served as a visiting Professor at Stanford University Computer Science department for seven years, and co-founded the Stanford AI Robot (STAIR) Project, which was the forerunner of the robot operating system (ROS) and PR2 robot developed at Willow Garage where he also served as Senior Scientist and manager. https://www.phronesisai.com/autonomous-drug-design daily 0.75 2025-06-23 https://www.phronesisai.com/privacy-policy daily 0.75 2025-06-23 https://www.phronesisai.com/eli-eisenberg daily 0.75 2025-06-23 https://images.squarespace-cdn.com/content/v1/6859db72168baf4d2384e4e3/1750719367175-Y4YNR1HQ3BYZ71ROL3AW/Touched+Up_190308-Provisors-06-Eli-Eisenberg-007_Web.jpg Eli Eisenberg - Eli Eisenberg Eli Eisenberg has more than 40 years of hands on experience in the financial and business management of entrepreneurial companies. From October, 2019, to April 2021, Mr. Eisenberg was CEO of Steril-Aire, a manufacturer of Ultraviolet Germicidal Devices. While at the helm of Steril-Aire, Mr. Eisenberg shepherded the company through a $70 million sale to one of the largest privately held companies in the United States. As founder and CEO of Straight Line Management™, he specializes in providing financial expertise and mentoring to high-potential early stage companies. Mr. Eisenberg helps them to increase profitability, secure funding, evaluate and capitalize on opportunities, streamline financial operations, and get the financial side of the business under control. Since launching his Straight Line Management consulting company in 1991, he has served as a trusted advisor to more than 100 early-stage companies across a variety of industries including software and game companies, high and low tech manufacturing companies, wholesale distribution companies, product and services companies. As CEO and founder of Straight Line Management, Mr. Eisenberg works at the senior level, as a trusted advisor to CEOs, CFOs, Boards and investors. In high-potential companies, he counsels senior management and guides existing staff towards the identification of profitable business opportunities, the solution of complex financial problems, and the development of improved management systems. Mr. Eisenberg is well-known for his expertise in creating financial models on behalf of start-ups and early stage companies seeking outside investment. Prior to starting Straight Line Management, Mr. Eisenberg served as Chief Financial Officer for three high technology companies, served in senior financial and operational management positions (including VP of Finance and VP of Operations) in several other high growth companies, and established, ran and sold his own successful consumer products company. Mr. Eisenberg has extensive experience in strategic planning, capital raising strategies, financial management and forecasting, business plan preparation, and development and streamlining of management reporting systems and controls. He received his MBA from the University of California, Berkeley in 1976 and became a Certified Public Accountant in the State of California is 1978. https://www.phronesisai.com/home daily 1.0 2025-07-10 https://images.squarespace-cdn.com/content/v1/6859db72168baf4d2384e4e3/1750719380578-727TQDXK54RPBVTKYNRC/Abou-Gharbia+-pic+2.JPG https://images.squarespace-cdn.com/content/v1/6859db72168baf4d2384e4e3/1750719375063-12Z9Q4A2UXIVELMQ5JVH/Childers+headshot.jpg https://images.squarespace-cdn.com/content/v1/6859db72168baf4d2384e4e3/1750719375069-W9C1G3IWFOHTJMZBDYUW/NeilBioPic.jpg https://www.phronesisai.com/userfriendly-interface daily 0.75 2025-06-23 https://www.phronesisai.com/juan-ochoa daily 0.75 2025-06-23 https://images.squarespace-cdn.com/content/v1/6859db72168baf4d2384e4e3/1750719374149-NJYC15TKPOJYT6XNTZRJ/JGO+PIC.jpg Juan Ochoa - Juan G. Ochoa, MD. Dr. Juan G. Ochoa is a highly esteemed Professor of Neurology at the University of South Alabama, recognized for his extensive expertise in clinical neurophysiology and neurological disorders. With decades of experience, Dr. Ochoa has made significant contributions to the understanding and treatment of complex neurological conditions through his innovative research and clinical practice. Dr. Ochoa has held pivotal roles such as Director of the USA Epilepsy Program and the EEG Lab/Epilepsy Monitoring Unit at Shands Jacksonville Medical Center. His board certifications in Neurology, Clinical Neurophysiology, and Epilepsy from the American Board of Psychiatry & Neurology highlight his deep knowledge and commitment to the field. Throughout his career, Dr. Ochoa has been honored with numerous teaching awards and has authored a wealth of publications in prestigious medical journals. His work on EEG source modeling and high-frequency oscillation activation has set new benchmarks in neurophysiological research and clinical practice. Dr. Ochoa’s participation brings unparalleled expertise and a forward-thinking approach to neurological health, and his insights foster innovative and interesting research in the field of neurology. https://www.phronesisai.com/our-team daily 0.75 2025-11-04 https://images.squarespace-cdn.com/content/v1/6859db72168baf4d2384e4e3/1750719375063-12Z9Q4A2UXIVELMQ5JVH/Childers+headshot.jpg Our Team https://images.squarespace-cdn.com/content/v1/6859db72168baf4d2384e4e3/1750719375069-W9C1G3IWFOHTJMZBDYUW/NeilBioPic.jpg Our Team https://images.squarespace-cdn.com/content/v1/6859db72168baf4d2384e4e3/1750719376988-B9311JAMROYH707AJ15S/iStock-1253467286.jpg Our Team https://images.squarespace-cdn.com/content/v1/6859db72168baf4d2384e4e3/1231e93f-70d9-4c28-ac5d-1beda2e89169/Michael-Bio-Pic.jpg Our Team https://images.squarespace-cdn.com/content/v1/6859db72168baf4d2384e4e3/315623a5-b8e1-44f6-9b8d-11554315690b/fgsalituro+headshot.jpg Our Team https://images.squarespace-cdn.com/content/v1/6859db72168baf4d2384e4e3/87fdfcd8-ee27-4d15-80ec-2c44b602d93d/KirkBioPic.jpg Our Team https://images.squarespace-cdn.com/content/v1/6859db72168baf4d2384e4e3/8b800e80-7da4-42c0-83d0-aa9fdc9df492/Magid+Abou-Gharbia-pic+1.jpg Our Team https://images.squarespace-cdn.com/content/v1/6859db72168baf4d2384e4e3/4a38abaf-2435-4739-82f4-59f5a46d9cf4/JGO+PIC.jpg Our Team https://images.squarespace-cdn.com/content/v1/6859db72168baf4d2384e4e3/1002e6b7-650f-462a-9365-2ce7b59be1d3/Croland_Thomas_headshot_compressed.jpg Our Team https://images.squarespace-cdn.com/content/v1/6859db72168baf4d2384e4e3/61c4ae31-0a56-436f-bb36-29332663b993/Will-Bio-Pic_upscayl_4x_upscayl-standard-4x.jpg Our Team https://images.squarespace-cdn.com/content/v1/6859db72168baf4d2384e4e3/05b5cc3d-cfce-4c2e-8b95-67b31a27924c/Rick+Bio+Pic+%281%29_upscayl_4x_upscayl-standard-4x.jpg Our Team https://images.squarespace-cdn.com/content/v1/6859db72168baf4d2384e4e3/bf656f64-5350-4e16-82bf-29c1b68ef0cb/Touched+Up_190308-Provisors-06-Eli-Eisenberg-007_Web.jpg Our Team https://images.squarespace-cdn.com/content/v1/6859db72168baf4d2384e4e3/240d1b07-96f7-49e8-9fdd-261c74ad5d86/Thomas+Lectka+picture_upscayl_4x_upscayl-standard-4x.jpg Our Team https://www.phronesisai.com/new-page daily 0.75 2025-06-23 https://www.phronesisai.com/contact daily 0.75 2025-06-23 https://www.phronesisai.com/advanced-neural-screening daily 0.75 2025-06-23 https://www.phronesisai.com/douglas-bordewieck daily 0.75 2025-06-23 https://images.squarespace-cdn.com/content/v1/6859db72168baf4d2384e4e3/1750719378050-JHCR5IQH6ET1HAFUL5X2/Douglas+Headshot.png DOUGLAS W. BORDEWIECK - DOUGLAS W. BORDEWIECK, JD Mr. Bordewieck is a highly experienced civil litigation attorney. For thirty years, he was associated with the Los Angeles-based law firm Mitchell, Silberberg & Knupp, where he exclusively worked in the firm’s Litigation Department, assisting over time in the prosecution and defense of nearly two hundred lawsuits. His litigation practice emphasized cases presenting intellectual property, environmental, regulatory, antitrust, and business tort issues. For ten years he also served as Adjunct Professor of Law at Cornell Law School, where he taught courses and seminars in Patent Law, Trademark Law, Federal Litigation, and Environmental Litigation. After obtaining his B.A. from Swarthmore College, Mr. Bordewieck worked for three years as an economist in the Carter Administration. He then attended Harvard Law School, obtaining his J.D. degree cum laude. Despite his experience litigating matters in court, Mr. Bordewieck strongly advocates the inclusion of arbitration clauses in commercial contracts, and the resolution of matters through alternative dispute resolution methods rather than litigation. Now self-employed, Mr. Bordewieck currently serves as de facto outside general counsel for nearly twenty companies located throughout the country. https://www.phronesisai.com/thomas-lectka daily 0.75 2025-06-23 https://images.squarespace-cdn.com/content/v1/6859db72168baf4d2384e4e3/1750719378986-MLGWGRCAU6C6A0SYA1MV/Thomas+Lectka+picture.jpg Thomas Lectka - Dr. Thomas Lectka, Ph.D. Currently a Professor of Chemistry at John Hopkins University, Dr. Thomas Lectka is an accomplished researcher with over 135 peer reviewed publications. Tom Lectka graduated from Oberlin College with highest honors in Chemistry (B.A.) in 1985. He received his Ph.D. from Cornell University in 1990 (study with Professor John McMurry) whereupon he was an ACS Organic Division Fellow. He performed postdoctoral studies as an Alexander von Humboldt Fellow at Heidelberg (1991, study with Rolf Gleiter), and as an NIH Fellow at Harvard University (1992-1994, study with Professor David Evans). He joined the faculty of the Chemistry Department of Johns Hopkins in 1994, was promoted to the Jean and Norman Scowe Professorship in 2012, and served as Chairman of thee Graduate Admissions Committee from 2008-2017. He has been the recipient of an NIH First Award, an NSF Career Award, an Eli Lilly Grantee Award, a Sloan Fellowship, a Dreyfus-Teacher-Scholar Award, a John Simon Guggenheim Memorial Fellowship, and he was honored as the ACS Maryland Chemist of the Year in 2017. https://www.phronesisai.com/francesco daily 0.75 2025-06-27 https://images.squarespace-cdn.com/content/v1/6859db72168baf4d2384e4e3/1750719379787-VWNIW0IQJ05ARWYQOFAZ/fgsalituro+headshot.jpg FRANCESCO G. SALITURO, Ph.D. - FRANCESCO G. SALITURO, Ph.D. Francesco G. Salituro, Ph.D., currently the founder of Salituro Med Chem Solutions, LLC, and has been a scientific leader in pharmaceutical industry since 1986 and has successfully driven drug discovery programs across multiple therapeutic areas. His work has resulted in 20 small molecule clinical candidates, including Dalzanemdor (SAGE-718), SAGE-324, SAG E-904, Neflamopimod, Decernotinib, Pimodivir, and 5 marketed drugs, Zulresso®, IDHIFA®,TIBSOVO®, Pyrukynd® and Zurzuvae®. Most recently, Francesco held the position of Sr Vice President of Discovery at Asteroid Therapeutics and prior to that held consulting/advisory positions at several early new companies such as Fog Pharma, Empress, Rectify, Vigil and Riva. Prior to that, he held the position of VP of Chemistry at Sage Therapeutics, from 2012 through 2020. Prior to Sage, Francesco held leadership positions at Agios Pharmaceuticals, Wyeth Research and Vertex Pharmaceuticals after initially joining Merrell Dow Pharmaceuticals in 1986. Francesco’s research has led to over 60 scientific publications and over 80 issued US Patents. Additionally, Francesco has been active within the Gordon Research Conferences, serving as Chairman of the prestigious GRC on Medicinal Chemistry in 2011. From September of 2014 through June 2023, Francesco served on the Board of Directors for the Epilepsy Foundation of New England (EFNE). He is also the co-founder of Joseph's HOPE Scholarship Fund, and more recently the Joseph's HOPE Emergency Fund, both of which are within the EFNE umbrella. Francesco received his B.S. Degree in Life Sciences from the University of Wisconsin-Parkside in 1980 and his Ph.D. in Medicinal Chemistry from the University of Wisconsin-Madison in 1984; he additionally held a postdoctoral position at University of Illinois-Champaign Urbana from 1984-1986. Outside of career and EFNE, Francesco pursues several passions including cooking, oenology , gardening, art collecting, and music. He has played in several rock bands over the past 18 years, including his current band Almost the Cure, all in support of his Joseph’s HOPE charities. Francesco is also co-owner of Audio Art, a state-of-the-art audio theater store located in Sudbury, MA. https://www.phronesisai.com/magid daily 0.75 2025-06-23 https://images.squarespace-cdn.com/content/v1/6859db72168baf4d2384e4e3/1750719380578-727TQDXK54RPBVTKYNRC/Abou-Gharbia+-pic+2.JPG Magid Abou-Gharbia - Magid Abou-Gharbia, Ph.D. Magid Abou-Gharbia, Ph.D, FRSC is currently Laura H. Carnell Professor of Medicinal Chemistry and Founding Director of the Moulder Center for Drug Discovery Research (MCDDR) at the School of Pharmacy, Temple University, Philadelphia, PA. As the Founding Director, he was responsible for Setting and implementing Moulder Center research strategies to bridging preclinical research with clinical research “from Bench to Patient-Bedside” and promoting the school’s research and entrepreneurial enterprise. Prior to joining Temple University in 2008, Magid spent 26 years at Wyeth Pharmaceuticals where he was Senior Vice President Discovery Research. In my role I directed research of 500 scientists at 4 US sites (PA, NJ, NY and MA) and 150 Chemists in Hyderabad, India. Abou-Gharbia’s research team efforts resulted in the Discovery of 10-marketed drugs across multiple therapeutic areas including two drugs for treatment of depression Effexor and Pristiq and four Drugs for treatment of Cancer and increasing the life expectancy of patients in need (Antibody Drug Conjugate Mylotarg, m- TOR inhibitor Torisel, Two Kinase inhibitors Bosulif and Neratinib). His research contributions in the past 15 years at Temple University resulted in establishing Moulder Center for Drug Discovery Research (https://www.youtube.com/watch?v=2yotuH6ZU0c), a State-of-the-Art academic Drug discovery Center. Moulder Center’s accomplishments included receiving several research grants and contract research (>$30M), the publications of numerous research papers in peer-reviewed journals, the filing of over 35 US patents and the formation of 4 spin off companies based on licensing of his Center’s IP to external companies. Magid received numerous awards for his scientific achievements and serves on the Scientific Advisory Board of several companies and Scientific and professional societies and has adjunct professor appointments at several universities in the US and abroad. His career research achievements resulted in more than 128 US patents, over 350 worldwide Patents, 325 publications, invited lectures and presentations. Current Research Activity: Medicinal Chemistry and Drug Design, particularly in the areas of glutamate Transporters Enhancers for treatment of cocaine addiction, Alcohol use and cerebral palsy , epigenetic modulators anti-cancer agents, anti-infectives and drugs for treating neuronal disorders . https://www.phronesisai.com/pipeline-1 daily 0.75 2025-07-03 https://www.phronesisai.com/our-team-1 daily 0.75 2025-06-27 https://images.squarespace-cdn.com/content/v1/6859db72168baf4d2384e4e3/1750719375052-EFD2FSJIQQT3UUECM5LF/IMG_4010.jpg Our Team (Copy) https://images.squarespace-cdn.com/content/v1/6859db72168baf4d2384e4e3/1750719375055-UCJ11KV9RLTXQZSKZVTJ/Will-Bio-Pic.jpeg Our Team (Copy) https://images.squarespace-cdn.com/content/v1/6859db72168baf4d2384e4e3/1750719375063-12Z9Q4A2UXIVELMQ5JVH/Childers+headshot.jpg Our Team (Copy) https://images.squarespace-cdn.com/content/v1/6859db72168baf4d2384e4e3/1750719375060-SV393RW7DM8SQVPTB3D5/Touched+Up_190308-Provisors-06-Eli-Eisenberg-007_Web.jpg Our Team (Copy) https://images.squarespace-cdn.com/content/v1/6859db72168baf4d2384e4e3/1750719375057-TLTET8WADRHX2ONT902K/Michael-Bio-Pic.jpg Our Team (Copy) https://images.squarespace-cdn.com/content/v1/6859db72168baf4d2384e4e3/1750719375082-ELVFVYGP0I1BHLB0TH7I/Douglas+Headshot.png Our Team (Copy) https://images.squarespace-cdn.com/content/v1/6859db72168baf4d2384e4e3/1750719375077-YNFXSK94WMWM99T18SC9/fgsalituro+headshot.jpg Our Team (Copy) https://images.squarespace-cdn.com/content/v1/6859db72168baf4d2384e4e3/1750719375066-5F3A6308UU50B9NY1INY/KirkBioPic.jpg Our Team (Copy) https://images.squarespace-cdn.com/content/v1/6859db72168baf4d2384e4e3/1750719375069-W9C1G3IWFOHTJMZBDYUW/NeilBioPic.jpg Our Team (Copy) https://images.squarespace-cdn.com/content/v1/6859db72168baf4d2384e4e3/1750719375072-8CHMW9F22KZ11U00SNPT/Thomas+Lectka+picture.jpg Our Team (Copy) https://images.squarespace-cdn.com/content/v1/6859db72168baf4d2384e4e3/1750719375074-TYKYX51HKRDQZ5QQYK6C/Magid+Abou-Gharbia-pic+1.jpg Our Team (Copy) https://images.squarespace-cdn.com/content/v1/6859db72168baf4d2384e4e3/1750719375079-WE9NSVUEW4QW177BWQ8A/JGO+PIC.jpg Our Team (Copy) https://images.squarespace-cdn.com/content/v1/6859db72168baf4d2384e4e3/1750719375085-4Z0WV9MME0UE5THAOLVH/image_67208961.JPG Our Team (Copy) https://images.squarespace-cdn.com/content/v1/6859db72168baf4d2384e4e3/2cbbc231-9e40-4704-8388-111a447e8f43/Rick+Bio+Pic+%281%29_upscayl_4x_upscayl-standard-4x.jpg https://images.squarespace-cdn.com/content/v1/5ec321c2af33de48734cc929/fd2c36d1-39c7-4ca7-a6f4-783cd349c48b/Rectangle+18.jpg https://images.squarespace-cdn.com/content/v1/5ec321c2af33de48734cc929/be8404a8-80ab-41d1-851b-e4ac02114ae5/Rectangle+17.jpg https://images.squarespace-cdn.com/content/v1/5ec321c2af33de48734cc929/70f656e4-cb7c-4982-9526-79abdb5f3c7c/Rectangle%2B17.jpg https://images.squarespace-cdn.com/content/v1/5ec321c2af33de48734cc929/ca5fa614-9b55-439b-98ed-e3f577995db3/Rectangle%2B16.jpg https://images.squarespace-cdn.com/content/v1/5ec321c2af33de48734cc929/10ba7d52-9907-4edd-aa50-92ffebc441c5/Rectangle%2B18.jpg https://www.phronesisai.com/new-page-1 daily 0.75 2025-07-03 https://www.phronesisai.com/tom-croland daily 0.75 2025-08-25 https://images.squarespace-cdn.com/content/v1/6859db72168baf4d2384e4e3/1002e6b7-650f-462a-9365-2ce7b59be1d3/Croland_Thomas_headshot_compressed.jpg Tom Croland - Thomas Croland Mechanical Engineering background and over 5 years of experience supporting advanced technologies in healthcare and life sciences. Proven expertise in system integration, user training, and technical support across complex laboratory and AI-driven platforms. Skilled in managing multi-site implementations, troubleshooting hardware/software issues, and ensuring regulatory and validation compliance. Strong customer-facing communicator with a track record of translating complex technical workflows into practical solutions that improve efficiency, reliability, and patient outcomes. Passionate about bridging engineering and healthcare to drive adoption of innovative diagnostic solutions.